The financial details of the agreement were not disclosed. (Representational image)
Ipca Laboratories has inked an agreement with Mangalore-headquartered Bhami Research Laboratories for access to a biologics delivery platform to develop monoclonal antibodies.
The licencing agreement grants Ipca access to BRL’s proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialisation of multiple monoclonal antibody products targeting oncology and inflammatory diseases, a note from the company said.
Ratnesh Jain, co-founder with WeTranslate, a life sciences business development company that played a role in the scientific and financial match-making between the two companies, told businessline that Ipca would undertake the development and there was a licensing fee for the technology transfer and royalites on sales, once the product was commercialised.
The financial details of the agreement were not disclosed.
Pranay Godha, Managing Director and Chief Executive, Ipca Laboratories, said the collaboration would help accelerate the development of “affordable biologics for people battling cancer and autoimmune disease worldwide.”
Surya Pai, Chief Executive and Co-Founder, BRL (a 12-year-old biotech company), said the partnership was designed to make patient care convenient, affordable and safe.
Akhil Shah, Director and Chief Executive, WeTranslate, said that world-class innovation deserved worldclass commercialisation pathways. “BRL has built a differentiated formulation technology platform, and Ipca brings the scale, expertise, and global reach required to unlock its full potential.”
Published on June 13, 2026
Source link
#Ipca #inks #licensing #agreement #Bhami #Research #biologics #delivery #platform #access
